Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis

Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers

(2016) Lianne Kearsley-Fleet et al.   RHEUMATOLOGY

The Humanistic and Economic Burden of Juvenile Idiopathic Arthritis in the era of Biologic Medication

(2015) Wendy Gidman et al.   Current Rheumatology Reports

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register

(2014) Marieke H Otten et al.   ANNALS OF THE RHEUMATIC DISEASES

Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors

(2014) M. L. Mannion et al.   JOURNAL OF RHEUMATOLOGY

Validity of juvenile idiopathic arthritis diagnoses using administrative health data

(2014) Elizabeth Stringer et al.   RHEUMATOLOGY INTERNATIONAL

Induction Therapy with Combination TNF Inhibitor and Methotrexate in Early Rheumatoid Arthritis

(2014) Yong Gil Hwang et al.   Current Rheumatology Reports

Importance of Adherence in the Outcome of Juvenile Idiopathic Arthritis

(2014) Claudio A. Len et al.   Current Rheumatology Reports

Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996-2009

(2013) L. R. Harrold et al.   JOURNAL OF RHEUMATOLOGY

Cost of Biologics in the Treatment of Juvenile Idiopathic Arthritis: A Factor not to be Overlooked

(2013) Femke H. M. Prince et al.   PEDIATRIC DRUGS

A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers

(2013) Bernard Ng et al.   BMJ Open

Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and

(2012) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Hydroxychloroquine Use and Decreased Risk of Diabetes in Rheumatoid Arthritis Patients

(2012) Androniki Bili et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Disease-modifying Antirheumatic Drug Use in the Treatment of Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA Registry

(2012) T. BEUKELMAN et al.   JOURNAL OF RHEUMATOLOGY

Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial

(2011) P. Tynjala et al.   ANNALS OF THE RHEUMATIC DISEASES

Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis

(2011) Carol A. Wallace et al.   ARTHRITIS AND RHEUMATISM

Biologic Disease-modifying Drug Treatment Patterns and Associated Costs for Patients with Rheumatoid Arthritis

(2011) STEPHAN McBRIDE et al.   JOURNAL OF RHEUMATOLOGY

An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register

(2011) F. H. M. Prince et al.   RHEUMATOLOGY

Adherence to methotrexate in juvenile idiopathic arthritis

(2011) Christina F. Pelajo et al.   RHEUMATOLOGY INTERNATIONAL

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

(2011) Timothy Beukelman et al.   ARTHRITIS CARE & RESEARCH

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

(2010) P. Quartier et al.   ANNALS OF THE RHEUMATIC DISEASES

Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis

(2010) Pengxiang Li et al.   VALUE IN HEALTH

Tumor Necrosis Factor Inhibitors in the Management of Juvenile Idiopathic Arthritis

(2010) Susan Shenoi et al.   PEDIATRIC DRUGS

Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs

(2009) Bijan J. Borah et al.   CURRENT MEDICAL RESEARCH AND OPINION

Utilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study

(2009) S. J. LEE et al.   JOURNAL OF RHEUMATOLOGY

Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies

(2009) Nicola P. Klein et al.   VACCINE

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

(2008) Nicolino Ruperto et al.   LANCET

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

(2008) Daniel J. Lovell et al.   NEW ENGLAND JOURNAL OF MEDICINE